Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27780295 | 0.80 | NR3C1 (0.54) | NR3C1PGRPIK3C3SGK1GRIA2 | |
| SCHEMBL2004236 | 0.76 | NR3C1 (0.59) | NR3C1PGRGRIA2LMNABRD4 | |
| SCHEMBL2003336 | 0.74 | RIPK1 (0.39) | GPBAR1SCN9A | |
| SCHEMBL2010372 | 0.73 | GPBAR1 (0.39) | CETPGPBAR1SCN9A | |
| SCHEMBL2008086 | 0.73 | NR3C1 (0.78) | NR3C1PGRPIK3C3SGK1 | |
| SCHEMBL2009788 | 0.72 | NR3C1 (0.58) | NR3C1PGRPIK3C3SGK1CNR2 | |
| SCHEMBL2006541 | 0.72 | NR3C1 (0.62) | NR3C1PGRPIK3C3SGK1SCN9A | |
| SCHEMBL27758653 | 0.70 | NR3C1 (0.49) | NR3C1PGRPIK3C3POLBSGK1 | |
| SCHEMBL2006759 | 0.68 | NR3C1 (0.55) | NR3C1PGRBRD4 | |
| SCHEMBL27780155 | 0.68 | GPBAR1 (0.41) | CETPGPBAR1SCN9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 131/4885PIK3C3 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.